ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
20
LSKB ANNOUNCES OFFICIAL NONPROPRIETARY NAMING OF APATINIB (YN968D1): RIVOCERANIB
admin
19
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENT IN ITS APATINIB-NIVOLUMAB COMBINATION STUDY
admin
18
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENTS IN THE US AND EUROPE FOR ITS ONGOING APATINIB PHASE 3 CLINICAL TRIAL IN ADVANCE
admin
17
LSKB ANNOUNCES ITS CLINICAL INITIATIVE TO STUDY THE SAFETY AND EFFICACY OF COMBINING APATINIB WITH IMMUNOTHERAPY
admin
16
LSKB ANNOUNCES COMPLETION OF ENROLLMENT FOR THE ANGEL STUDY OF RIVOCERANIB (APATINIB) IN GASTRIC CANCER
admin
15
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL CLINICAL COLLABORATION TO EVALUATE THE COMBINATION OF ANTI-ANGIOGENE
admin
14
LSKB ANNOUNCES MFDS APPROVAL TO INITIATE A PHASE I/IIA COMBINATION STUDY OF RIVOCERANIB AND PACLITAXEL AT ASAN MEDICAL CENTER (
admin
13
LSKB ANNOUNCES THAT ENROLLMENT HAS OPENED AT HUNTSMAN CANCER INSTITUTE FOR THE APPEASE STUDY COMBINING RIVOCERANIB AND PEMBROLI
admin
12
HLB Co., Ltd. launches multipurpose High-Speed Rescue Boat
admin
11
LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer
admin
<<
<
11
12
13
14
15